Monitor FDA meeting outcome for fasedienol's registrational pathway, as it will determine the company's clinical direction and capital needs. With cash only sufficient into 2027, a dilutive financing or partnership is likely within the next 12 months.
Price Chart
Executive Summary
Vistagen reported Q1 FY2027 results with a net loss of $0.30 per share, beating consensus of -$0.36 by 16.7%, and revenue of $1.48M (vs $0.17M consensus) driven by one-time sublicense recognition. Clinical updates were mixed: fasedienol's PALISADE-4 missed its primary endpoint but showed a signal in very severe SAD patients, with an FDA meeting planned. Cash of $31.7M funds operations into 2027 but not beyond a year, highlighting near-term financing risk.
Key Financial Metrics
Key Facts
- EPS of -$0.30 beat consensus -$0.36 by 16.7%
- Revenue of $1.48M beat $0.17M consensus, primarily from one-time sublicense recognition
- Net loss improved to $13.0M from $15.1M YoY
- Cash, equivalents, and marketable securities $31.7M; runway into 2027 but not beyond one year
- Fasedienol PALISADE-4 missed primary endpoint; post-hoc subgroup signal in very severe SAD
- FDA meeting planned for potential Phase 3 path forward for fasedienol
- Appointed new CMO and board member with neuroscience experience
Financial Impact
EPS beat of $0.06 (16.7%) and revenue beat of $1.31M (784%) on a one-time basis; net loss improved $2.1M YoY
Risk Factors
- Cash runway insufficient beyond one year; likely need for additional financing
- Fasedienol clinical program uncertain after PALISADE-4 miss; FDA may require additional trials
- Micro-cap volatility; historical T+20 returns on this ticker have been negative on average
- No approved products; revenue is non-recurring and minimal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345334 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.2676 $0.2432 | ▲ +9.12% | ▲ +7.13% | $0.2863 (−6.99%) |
Aug 14, 2026 7w ago | Press Release | $0.2676 $0.2432 | ▼ −9.12% | ▼ −7.13% | $0.2863 (+6.99%) |
Jul 31, 2026 9w ago | 8-K | $0.2410 $0.2529 | ▲ +4.94% | ▲ +1.95% | $0.2863 (+18.80%) |
Jun 30, 2026 13w ago | 8-K | $0.2260 $0.2302 | ▼ −1.86% | ▼ −2.89% | $0.2863 (−26.68%) |
Jun 17, 2026 15w ago | 8-K | $0.6702 $0.2400 | ▼ −64.19% | ▼ −64.72% | $0.2863 (−57.28%) |
Jun 15, 2026 15w ago | 8-K | $0.6900 $0.2461 | ▼ −64.33% | ▼ −64.53% | $0.2863 (−58.51%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.5731 $0.2492 | ▼ −56.52% | ▼ −58.41% | $0.2863 (−50.04%) |
Jun 9, 2026 16w ago | 8-K | $0.5351 $0.2492 | ▼ −53.43% | ▼ −57.05% | $0.2863 (−46.50%) |
May 19, 2026 19w ago | 8-K | $0.6400 $0.6702 | ▲ +4.72% | ▲ +3.98% | $0.2863 (−55.27%) |
May 12, 2026 20w ago | 8-K | $0.6200 $0.5400 | ▼ −12.90% | ▼ −11.18% | $0.2863 (−53.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access